HCM Marketplace

Irritable bowel syndrome (IBS) is a common disease affecting 10 - 20% of the total adult population, particularly women, in which recurrent abdominal pain or discomfort is associated with defecation or changes in bowel habit. The majority of sufferers have never consulted a physician about their symptoms and remain undiagnosed.

Datamonitor's Irritable Bowel Syndrome: Potentially profitable market is open for the taking examines key issues and unmet needs in the diagnosis and management of IBS; covering etiology, epidemiology, presentation, diagnosis, and current treatment strategies. In addition, the report explores the impact of safety concerns with newer treatment for IBS, including Novartis’s Zelnorm (tegaserod) and GSK’s Lotronex (alosetron), and what this could mean for manufacturers developing products for the potential treatment of IBS

Scope of this report

• Epidemiology and patient segmentation in irritable bowel syndrome (IBS), including a breakdown of the patient population by gender and symptom type
• Discussion of issues with regards to IBS patient presentation, referral patterns and diagnosis such as the new Rome III diagnostic criteria
• Overview of the current treatment controversies and unmet needs, including the market withdrawal of Novartis' Zelnorm (tegaserod)
• Analysis of clinical trial design in the R&D drug pipeline for new IBS drug therapies in 2007

Reasons to Purchase

• Quantify the key target segments of the IBS patient population across the seven major markets
• Gain insight into opinion leaders' thoughts on the major opportunities and challenges facing the IBS market
• Learn about key late-stage pipeline drugs and issues surrounding diagnosis and clinical trial design

Report Highlights

Despite the substantial impact IBS can have on sufferers' well being, about 70 - 80% of sufferers have not been formally diagnosed.

Physicians frequently do not recognize IBS as a 'distinct' disease. Continuing physician education is needed to change this attitude and improve diagnosis, particularly in the primary care setting. A simple and easily accessible diagnostic tool adapted specifically for non-specialists and clear peer reviewed treatment guidelines are needed.

The pipeline can be described as relatively innovative. The serotinergic class accounts for a third of candidates, however, the poor safety record and market withdrawal of Lotronex (alosetron) and Zelnorm has cast doubts over the potential of this class. FDA non-approval of cilansetron is another setback for the serotinergics.

To order or to receive a FREE excerpt of this pharmaceutical marketing special report,Irritable Bowel Syndrome: Potentially profitable market is open for the taking, produced by Datamonitor and distributed by ePharmaceuticals™, a division of HCPro, Inc., call 877/437-4276 or e-mail epharm@hcpro.com. Orders must be paid in full before shipment. All sales are final; no returns or refunds are permitted with this product.

• Reports

• Other Marketing Products